Your session is about to expire
← Back to Search
Remote Monitoring & Telemedicine for Leukemia Care
N/A
Waitlist Available
Led By Glen Peterson
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights
Study Summary
This trial assesses using technology to provide better care coordination and management, and referral to treatment, for BMT and CAR-T patients, with remote monitoring, telemedicine, and home care.
Who is the study for?
This trial is for adults aged 18-89 with leukemia who are stable enough to be discharged home after a bone marrow transplant or CAR-T therapy. They must have caregiver support, reliable phone and internet service, live within 45 minutes of the AMC in Denver, and agree to use technology for remote care.Check my eligibility
What is being tested?
The study tests an at-home oncology care program using BioIntelliSense BioButton and Memora Health platform for patients post-BMT or CAR-T. It includes remote monitoring, telemedicine, and home health services to improve care coordination.See study design
What are the potential side effects?
Since this trial focuses on technology-assisted care rather than medication, traditional side effects aren't applicable. However, participants may experience issues related to device wearability or technical difficulties with the platforms used.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 90 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Minutes RPM devices spent off-body
Number of CRS events confirmed by clinical evaluation
Number of alerts generated through RPM systems
+9 moreSecondary outcome measures
EPRO patient response rates
Length of stay for hospital admissions during study period
Number of ICU admissions during study period
+6 moreOther outcome measures
Overall caregiver satisfaction
Overall health care provider satisfaction
Overall patient satisfaction
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Post BMT or CAR-T patients receiving care at UCHealthExperimental Treatment2 Interventions
Participants will be recruited for this study from among three discrete patient populations:
Allogeneic BMT patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the Anschutz Medical Campus (AMC) for at least 90 days post-transplant.
Autologous BMT patients receiving care at UCHealth who are planning to reside in the Denver metro Area within 45 minutes of the AMC for at least 30 days post-transplant.
CAR-T patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the AMC for at least 30 days post treatment.
Find a Location
Who is running the clinical trial?
University of Colorado, DenverLead Sponsor
1,738 Previous Clinical Trials
2,149,515 Total Patients Enrolled
16 Trials studying Leukemia
566 Patients Enrolled for Leukemia
Reimagine CareUNKNOWN
1 Previous Clinical Trials
10 Total Patients Enrolled
Glen PetersonPrincipal InvestigatorUniversity of Colorado, Denver
1 Previous Clinical Trials
20 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have someone to take care of me at home all the time.My doctor says I am stable enough to go home for outpatient care.I have received a bone marrow transplant or CAR-T therapy.I am between 18 and 89 years old.I can send and receive unlimited texts for the study without any issues.
Research Study Groups:
This trial has the following groups:- Group 1: Post BMT or CAR-T patients receiving care at UCHealth
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any vacancies for prospective candidates in this clinical trial?
"Absolutely. Information found on clinicaltrials.gov illustrates that this trial is currently recruiting patients, which first began being sought after on March 29th 2023 and was revised most recently on April 20th of the same year. The study requires 10 participants from a single location to take part in it."
Answered by AI
Is the age range for participation in this study inclusive of individuals aged 30 or younger?
"The eligibility parameters for this trial stipulate that potential participants must be 18 years of age or older, with a maximum permissible age of 89."
Answered by AI
Is it possible to participate in this research?
"This clinical trial requires participants to be aged between eighteen and eighty-nine, with a diagnosis of leukemia. The overall recruitment quota is ten individuals."
Answered by AI
How many participants have enrolled in this trial to date?
"Affirmative. According to the clinicaltrials.gov website, this medical trial is currently seeking participants and was last updated on April 20th 2023; it first appeared online on March 29th of that same year. The study requires 10 individuals based at a single location for enrollment."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger